EGFR and non-small cell lung carcinoma: Based on these results, the Food and Drug Administration (FDA) granted an accelerated approval for mobocertinib as a second-line therapy to treat NSCLC with EGFR exon 20 insertion mutations with progression on platinum-based chemotherapy in September 2021 [44].